Division of Clinical Neurology and Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
Neurology. 2013 Feb 26;80(9):857-64. doi: 10.1212/WNL.0b013e318284070c.
We performed a systematic review to assess alterations in measures of diffusion tensor imaging (DTI) in parkinsonian syndromes, exploring the potential role of DTI in diagnosis and as a candidate biomarker.
We searched EMBASE and Medline databases for DTI studies comparing parkinsonian syndromes or related dementias with controls or another defined parkinsonian syndrome. Key details for each study regarding participants, imaging methods, and results were extracted. Estimates were pooled, where appropriate, by random-effects meta-analysis.
Of 333 results, we identified 43 studies suitable for inclusion (958 patients, 764 controls). DTI measures detected alterations in all parkinsonian syndromes, with distribution varying differentially with disease type. Nine studies were included in a meta-analysis of the substantia nigra in Parkinson disease. A notable effect size was found for lowered fractional anisotropy in the substantia nigra for patients with Parkinson disease vs controls (-0.639, 95% confidence interval -0.860 to -0.417, p < 0.0001).
DTI may be a promising biomarker in parkinsonian syndromes and have a future role in differential diagnosis. Larger cohort studies are required to investigate some encouraging preliminary findings. Given the complexity of the parkinsonian syndromes, it is likely that any potential DTI biomarker would be used in combination with other relevant biomarkers.
我们进行了一项系统评价,以评估帕金森综合征患者的弥散张量成像(DTI)测量值的变化,探索 DTI 在诊断中的潜在作用和候选生物标志物。
我们在 EMBASE 和 Medline 数据库中搜索了比较帕金森综合征或相关痴呆与对照组或另一种明确的帕金森综合征的 DTI 研究。从每个研究中提取有关参与者、成像方法和结果的关键细节。在适当的情况下,通过随机效应荟萃分析对估计值进行汇总。
在 333 项结果中,我们确定了 43 项适合纳入的研究(958 名患者,764 名对照)。DTI 测量值在所有帕金森综合征中均检测到改变,其分布随疾病类型而不同。9 项研究纳入了帕金森病患者黑质的荟萃分析。与对照组相比,帕金森病患者黑质的各向异性分数明显降低(-0.639,95%置信区间-0.860 至-0.417,p < 0.0001)。
DTI 可能是帕金森综合征有前途的生物标志物,在鉴别诊断中具有未来的作用。需要更大的队列研究来进一步调查一些有希望的初步发现。鉴于帕金森综合征的复杂性,任何潜在的 DTI 生物标志物都可能与其他相关生物标志物结合使用。